View Past PerformanceAccuStem Sciences 대차대조표 건전성재무 건전성 기준 점검 1/6AccuStem Sciences 의 총 주주 지분은 $-3.9M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $1.5M 및 $5.4M 입니다.핵심 정보0%부채/자본 비율US$0부채이자보상배율n/a현금US$12.21k자본-US$3.87m총부채US$5.42m총자산US$1.55m최근 재무 건전성 업데이트공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2026, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • May 16AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.모든 업데이트 보기Recent updates공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2026, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • May 16AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 11Accustem Sciences Inc. Announces Resignation of Jeff Fensterer as Chief Operating Officer, Effective as of June 16, 2023On June 5, 2023, Jeff Fensterer, the Chief Operating Officer of AccuStem Sciences Inc. resigned his position with the Company for personal reasons, effective as of June 16, 2023. Jeff Fensterer will be moving to a consulting position with the Company.공시 • Nov 17Accustem Sciences Inc. Appoints Sean McDonald to Its Board of DirectorsAccuStem Sciences Inc. announced the appointment of Sean McDonald to its board of directors which will now comprise five members. Sean joins the company board while serving as the CEO of Ocugenix. Sean served as a director at Aethon from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Prior to that, from 2001 to 2014, Sean served as the CEO of Precision Therapeutics, one of the first biotechnology companies to marry breakthroughs in understanding of cancer biology and the use of machine learning with the goal of developing products that would help cancer patients get the most effective cancer treatment. From 2002 to 2008, Sean was also a director on the board of Respironics where he was a member of the audit and compensation committees leading up to its $5.1 billion acquisition by Phillips. Sean started his career in healthcare by founding Automated Healthcare which was one of the first companies to develop systems for automating the dispensing and administration of medication in hospital pharmacies. Mr. McDonald grew the organization from its inception to over 1,000 employees and oversaw the building of market access, clinical, product development and sales and marketing organizations. Automated Healthcare was ultimately acquired by McKesson Corporation where Sean became President of the automation group.공시 • Sep 15Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022, at 09:00 Eastern Daylight. Location: the offices of Sheppard Mullin Richter & Hampton LLP located at 30 Rockefeller Plaza New York New York United States Agenda: To elect four members to board of directors; to ratify the appointment of Mazars USA LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve an amendment to Amended and Restated Certificate of Incorporation (the “Charter”), to effect a reverse stock split of outstanding shares of common stock by a ratio of any whole number between one-for-two and one-for-fifteen, at any time prior to October 10, 2023, the implementation and timing of which shall be subject to the discretion of our board of directors; and to transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.공시 • Apr 07Accustem Sciences Inc. announced that it expects to receive $2.67594 million in fundingAccustem Sciences Inc. announced a private placement of 1,337,970 common shares at the price of $2 per share for gross proceeds of $2,675,940 on April 5, 2022.공시 • Apr 06Accustem Sciences Inc. Appoints Wendy Blosser as Director to Serve on the BoardOn March 30, 2022, the Board of Directors of Accustem Sciences Inc. appointed Wendy Blosser, the company’s Chief Executive Officer as a director to serve on the Board and to hold office until the next annual meeting of stockholders and until her successor is duly elected and qualified, or until her prior death, resignation, retirement, disqualification or other removal.공시 • Mar 06+ 1 more updateAccuStem Sciences, Inc. Appoints New Executive Leadership TeamAccustem Sciences Inc. announced the formation of its executive leadership team as the first major step toward commercializing new products in the oncology space. Wendy Blosser, a commercial executive with extensive leadership experience at diagnostic companies in the oncology sector, has been named a member of the board of directors for AccuStem. Wendy most recently served as the Chief Commercial Officer for Agendia, a leading breast oncology company, where she led the organization to its highest sales volume and revenue since its inception. Prior to that, Wendy served as the Chief Commercial Officer at Biodesix where she oversaw the launch and rapid growth of its blood-based genomic testing, GeneStrat. Also joining the leadership team are Jeff Fensterer, as Chief Operations Officer, and Joe Flanagan, as Chief Business Officer. Jeff brings an exceptional track record in long term strategic planning that is enhanced by his experience in a broad spectrum of roles including marketing, sales, market access, lab operations and product development. Joe brings 25 years of sales excellence as a strategic expert in the commercial development and successful launch of new and on-market products. Both executives have led companies at various stages, from early start up to Fortune 500, to consistent and rapid growth in sales volume and revenue, most recently with Agendia.재무 상태 분석단기부채: ACUT 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.장기 부채: ACUT는 마이너스 주주 지분을 갖고 있어 장기 부채를 충당하지 못하는 단기 자산보다 더 심각한 상황입니다.부채/자본 비율 추이 및 분석부채 수준: ACUT 부채가 없습니다.부채 감소: ACUT는 주주 지분이 음수이므로 부채가 시간이 지남에 따라 감소했는지 확인할 필요가 없습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: ACUT 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 5.5 %의 역사적 비율로 계속 감소할 경우 ACUT 의 현금 활주로는 1년 미만입니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 02:19종가2026/05/18 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AccuStem Sciences, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2026, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • May 16AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2026, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • May 16AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 11Accustem Sciences Inc. Announces Resignation of Jeff Fensterer as Chief Operating Officer, Effective as of June 16, 2023On June 5, 2023, Jeff Fensterer, the Chief Operating Officer of AccuStem Sciences Inc. resigned his position with the Company for personal reasons, effective as of June 16, 2023. Jeff Fensterer will be moving to a consulting position with the Company.
공시 • Nov 17Accustem Sciences Inc. Appoints Sean McDonald to Its Board of DirectorsAccuStem Sciences Inc. announced the appointment of Sean McDonald to its board of directors which will now comprise five members. Sean joins the company board while serving as the CEO of Ocugenix. Sean served as a director at Aethon from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Prior to that, from 2001 to 2014, Sean served as the CEO of Precision Therapeutics, one of the first biotechnology companies to marry breakthroughs in understanding of cancer biology and the use of machine learning with the goal of developing products that would help cancer patients get the most effective cancer treatment. From 2002 to 2008, Sean was also a director on the board of Respironics where he was a member of the audit and compensation committees leading up to its $5.1 billion acquisition by Phillips. Sean started his career in healthcare by founding Automated Healthcare which was one of the first companies to develop systems for automating the dispensing and administration of medication in hospital pharmacies. Mr. McDonald grew the organization from its inception to over 1,000 employees and oversaw the building of market access, clinical, product development and sales and marketing organizations. Automated Healthcare was ultimately acquired by McKesson Corporation where Sean became President of the automation group.
공시 • Sep 15Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022, at 09:00 Eastern Daylight. Location: the offices of Sheppard Mullin Richter & Hampton LLP located at 30 Rockefeller Plaza New York New York United States Agenda: To elect four members to board of directors; to ratify the appointment of Mazars USA LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve an amendment to Amended and Restated Certificate of Incorporation (the “Charter”), to effect a reverse stock split of outstanding shares of common stock by a ratio of any whole number between one-for-two and one-for-fifteen, at any time prior to October 10, 2023, the implementation and timing of which shall be subject to the discretion of our board of directors; and to transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
공시 • Apr 07Accustem Sciences Inc. announced that it expects to receive $2.67594 million in fundingAccustem Sciences Inc. announced a private placement of 1,337,970 common shares at the price of $2 per share for gross proceeds of $2,675,940 on April 5, 2022.
공시 • Apr 06Accustem Sciences Inc. Appoints Wendy Blosser as Director to Serve on the BoardOn March 30, 2022, the Board of Directors of Accustem Sciences Inc. appointed Wendy Blosser, the company’s Chief Executive Officer as a director to serve on the Board and to hold office until the next annual meeting of stockholders and until her successor is duly elected and qualified, or until her prior death, resignation, retirement, disqualification or other removal.
공시 • Mar 06+ 1 more updateAccuStem Sciences, Inc. Appoints New Executive Leadership TeamAccustem Sciences Inc. announced the formation of its executive leadership team as the first major step toward commercializing new products in the oncology space. Wendy Blosser, a commercial executive with extensive leadership experience at diagnostic companies in the oncology sector, has been named a member of the board of directors for AccuStem. Wendy most recently served as the Chief Commercial Officer for Agendia, a leading breast oncology company, where she led the organization to its highest sales volume and revenue since its inception. Prior to that, Wendy served as the Chief Commercial Officer at Biodesix where she oversaw the launch and rapid growth of its blood-based genomic testing, GeneStrat. Also joining the leadership team are Jeff Fensterer, as Chief Operations Officer, and Joe Flanagan, as Chief Business Officer. Jeff brings an exceptional track record in long term strategic planning that is enhanced by his experience in a broad spectrum of roles including marketing, sales, market access, lab operations and product development. Joe brings 25 years of sales excellence as a strategic expert in the commercial development and successful launch of new and on-market products. Both executives have led companies at various stages, from early start up to Fortune 500, to consistent and rapid growth in sales volume and revenue, most recently with Agendia.